Developer docs
API playgroundTry for free, no card

Search company profiles

Medasense

Full company profile

uuid0002fj4

Namestring
Medasense
Legal namestring
Medasense Biometrics Ltd.
Websiteurl
medasense.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Medasense (www.medasense.com) offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedication Medasense’s flagship product, the PMD-200 with its NOL® index, is a unique platform that objectively monitors and quantifies the patient’s pain response by means of artificial intelligence and a proprietary non-invasive sensor platform. The PMD-200 is used to optimize pain management in operating rooms and critical care settings, where patients are unable to communicate – a $5B market. The company’s pipeline cloud-based solutions for clinics and home, leveraging the NOL technology, addresses an additional $15B global market. The PMD-200 is distributed in Europe exclusively by Medtronic (NYSE:MDT), is cleared for marketing also in Canada, Latin America and Australia, and enables connectivity with Philips patient monitors. Clinical studies have demonstrated its impact on patient safety and outcomes, including opioid-sparing. Medasense was founded in 2008 and based in Ramat Gan, Tel Aviv, Israel.

Short descriptiontext

Medasense offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedication.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRamat Gan, Israel
HQ citystring
Ramat Gan
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nociception monitoring systems, patient pain monitoring, anesthesia monitoring equipment, physiological signal processing, personalized analgesic dosing
Industry1 code
PRIMARYHLAHACAA
Vital Signs Monitoring (Multi-parameter, Spot-Check & Continuous)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Nociception Monitoring Systems
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1PMD-200 Hardware Sales
TypeHardware Sales
Description

Sale of PMD-200 patient monitoring devices with NOL technology to hospitals and healthcare facilities. The device is a capital medical equipment purchase with associated consumables for continuous use.

medasense.com
2Distribution Partnerships
TypeLicensing Royalties
Description

Revenue generated through distribution partnerships where partners resell and distribute Medasense products in their respective territories (e.g., Medtronic Israel distribution agreement).

medasense.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise Hospital Procurement - Quote-based pricing
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Pricing available through request a demo and quote template process. Hospital capital purchase evaluation process includes clinical evaluation, ROI analysis, and value analysis committee review.

medasense.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1PMD-200™
Description

Flagship pain response (nociception) monitoring system with NOL technology for use during general anesthesia and in critical care settings.

medasense.com
+2 more records
Core offering1 text field

Medasense develops and sells the PMD-200 patient monitor for continuous, real-time measurement of nociception during surgery and critical care. The system uses a finger-probe sensor and proprietary machine-learning algorithms to translate multiple physiological signals into an NOL Index that clinicians use to personalize analgesic dosing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 33% reduction in reported postoperative pain scores in PACU
+6 more records
Product overview1 text field

Medasense offers a unified product portfolio centered on its proprietary NOL (Nociception Level Index) AI technology for objective pain monitoring. The core offering is the PMD-200 patient monitor, which provides real-time nociception quantification during surgery and critical care. The pipeline includes NOLedge, which aims to expand AI capabilities into pain prediction, stratification, and prevention across broader care settings. The company also develops an NOL OEM module for integration into partner monitoring platforms.

Product and service1 record
1PMD-200™
CategoryMedical patient monitoring equipment
Description

A flagship patient monitor that uses a finger-probe sensor and proprietary AI algorithms to continuously display the NOL (Nociception Level Index) and quantify a patient's nociception during surgery and critical care, enabling clinicians to personalize analgesic dosing.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Philips (Capsule Medical Device Information Platform)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-07-07
Description

Integration with Philips Capsule MDIP enables streaming of NOL Index and trend data directly to hospital EHR systems including Epic, Oracle/Cerner, MEDITECH and others. Provides automated EMR documentation, clinical surveillance, and analytics capabilities.

medasense.com
2Jefferson Health / Thomas Jefferson University
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2026-03-31
Description

Clinical trial collaboration as part of Israel-U.S. HealthTech Pilot Program to study NOL technology during spine surgery procedures at Jefferson's medical center in Philadelphia. Jefferson performs approximately 3,000 spine surgeries annually. Study aims to generate real-world clinical evidence and health economic data for U.S. market entry.

einpresswire.com
3Blink Device Company
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2025-01-28
Description

Joint grant awarded by BIRD Foundation for development of personalized anesthesia platform incorporating NOL Nociception Monitoring. Grant accelerates development of NOL OEM module for rapid scalability and collaboration with global strategic partners.

medasense.com
4Medtronic Israel
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-12-12
Description

Medtronic Israel partnership for distribution of NOL Nociception Monitoring technology. Medtronic serves as a strategic distribution partner handling sales and distribution of Medasense products in Israel market.

binghamtonhomepage.com
5Mindray
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Commercial partner displaying Medasense logo on website partner section, indicating distribution or integration relationship.

medasense.com
6Nihon Kohden
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Commercial partner displaying Medasense logo on website partner section, indicating distribution or integration relationship.

medasense.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1MDoloris Medical Systems
TypeDirect peer
Description

French medical device company that markets the ANI (Analgesia Nociception Index) monitor — the most direct competitor to Medasense's NOL technology for objective intra-operative nociception monitoring. Both target anesthesiologists with AI-derived indices for personalizing analgesic dosing.

2Quantium Medical
TypeDirect peer
Description

Spanish developer of the qCON and qNOX nociception/antinociception monitoring indices. Competes head-to-head with Medasense's NOL in the same anesthesiology use case of guiding opioid and analgesic titration during surgery.

3Masimo
TypeBroad incumbent
Description

Global patient monitoring leader whose SedLine EEG-based anesthesia monitoring and Surgical Pleth Index (SPI) overlap with Medasense's OR pain-monitoring niche. Masimo's installed base at U.S. hospitals and broad multiparameter platform make it the most likely large incumbent to compete for the same anesthesia-workflow slot.

4Dräger
TypeBroad incumbent
Description

Leading anesthesia and patient monitoring vendor whose Perseus and Zeus anesthesia workstations include analgesia-monitoring adjuncts. PMD-200 attaches to Dräger-equipped ORs, positioning Dräger as both an integration partner and a potential competitor if it bundles its own nociception feature.

5GE Healthcare
TypeBroad incumbent
Description

Major patient monitoring and anesthesia (Carestation) platform provider. Its installed base in U.S. ORs is the same point of attachment for Medasense, and its hemodynamic monitoring roadmap is the most likely incumbent vector for in-platform nociception features.

6Philips
TypeBroad incumbent
Description

Both an integration partner (via Capsule MDIP streaming NOL data to hospital EHRs) and a broad patient-monitoring incumbent. Philips's IntelliVue and Capsule footprint make it a powerful distribution ally and a natural competitive threat if it integrates its own analgesia index.

7Mindray
TypeBroad incumbent
Description

Global patient monitoring and anesthesia vendor listed as a Medasense distribution partner. Mindray's broad OR monitor portfolio and competitive pricing in emerging markets make it both a channel ally and a future bundling competitor.

8Nihon Kohden
TypeBroad incumbent
Description

Japanese patient monitoring leader with significant U.S. hospital presence and listed as a Medasense distribution partner. Its anesthesia and vital signs monitors are direct attachment points for PMD-200.

9Medtronic
TypeBroad incumbent
Description

Largest medical device franchise globally, currently distributing NOL in Israel through its local affiliate. Medtronic's portfolio breadth, hospital relationships, and investor arm (Baxter Ventures participated in Medasense's Series C) position it as the most strategic large incumbent — both as a near-term partner and a long-term acquirer/competitor.

10Edwards Lifesciences
TypeBroad incumbent
Description

Hemodynamic monitoring leader (HemoSphere, FloTrac) competing for the same anesthesia/OR monitoring budget. While Edwards focuses on hemodynamic rather than nociception indices, its premium pricing model and KOL relationships make it a comparable high-value, evidence-driven OR monitoring franchise.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medasense

Nociception Monitoring Systemsmedasense.com

Medasense offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedication.

What Medasense does

Medasense (www.medasense.com) offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedication Medasense’s flagship product, the PMD-200 with its NOL® index, is a unique platform that objectively monitors and quantifies the patient’s pain response by means of artificial intelligence and a proprietary non-invasive sensor platform. The PMD-200 is used to optimize pain management in operating rooms and critical care settings, where patients are unable to communicate – a $5B market. The company’s pipeline cloud-based solutions for clinics and home, leveraging the NOL technology, addresses an additional $15B global market. The PMD-200 is distributed in Europe exclusively by Medtronic (NYSE:MDT), is cleared for marketing also in Canada, Latin America and Australia, and enables connectivity with Philips patient monitors. Clinical studies have demonstrated its impact on patient safety and outcomes, including opioid-sparing. Medasense was founded in 2008 and based in Ramat Gan, Tel Aviv, Israel.

Medasense firmographics

Firmographics
Name
Medasense
Legal name
Medasense Biometrics Ltd.
Website
https://medasense.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Medasense offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedication.
Ownership category
akta.pro rank

Medasense industry classification

Industry
Product category
Nociception Monitoring Systems
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHACAA
Vital Signs Monitoring (Multi-parameter, Spot-Check & Continuous)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Nociception monitoring systems
  • Patient pain monitoring
  • Anesthesia monitoring equipment
  • Physiological signal processing
  • Personalized analgesic dosing

Where Medasense is headquartered

Location

Headquarters

HQ city
Ramat Gan
HQ country
Israel
HQ region
Middle East

Offices3 records

Markets served

Medasense business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. PMD-200 Hardware Sales: Sale of PMD-200 patient monitoring devices with NOL technology to hospitals and healthcare facilities. The device is a capital medical equipment purchase with associated consumables for continuous use.
  2. Distribution Partnerships: Revenue generated through distribution partnerships where partners resell and distribute Medasense products in their respective territories (e.g., Medtronic Israel distribution agreement).

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractEnterprise Hospital Procurement - Quote-based pricing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Medasense product offering

Product offering

Core offering

Medasense develops and sells the PMD-200 patient monitor for continuous, real-time measurement of nociception during surgery and critical care. The system uses a finger-probe sensor and proprietary machine-learning algorithms to translate multiple physiological signals into an NOL Index that clinicians use to personalize analgesic dosing.

Product overview

Medasense offers a unified product portfolio centered on its proprietary NOL (Nociception Level Index) AI technology for objective pain monitoring. The core offering is the PMD-200 patient monitor, which provides real-time nociception quantification during surgery and critical care. The pipeline includes NOLedge, which aims to expand AI capabilities into pain prediction, stratification, and prevention across broader care settings. The company also develops an NOL OEM module for integration into partner monitoring platforms.

Differentiator

Problem solved

Functional benefit

Brands

  • PMD-200™: Flagship pain response (nociception) monitoring system with NOL technology for use during general anesthesia and in critical care settings.
  • NOLedge™
  • NOL® Index

Products and services

  • PMD-200™ A flagship patient monitor that uses a finger-probe sensor and proprietary AI algorithms to continuously display the NOL (Nociception Level Index) and quantify a patient's nociception during surgery and critical care, enabling clinicians to personalize analgesic dosing.

Quantifiable outcome

  • 33% reduction in reported postoperative pain scores in PACU
  • +6 more outcomes

Companies that use Medasense

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Medasense technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

Medasense partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, key and minor.

  • Philips (Capsule Medical Device Information Platform)coreTechnology or Integration · 7 July 2026Integration with Philips Capsule MDIP enables streaming of NOL Index and trend data directly to hospital EHR systems including Epic, Oracle/Cerner, MEDITECH and others. Provides automated EMR documentation, clinical surveillance, and analytics capabilities.
  • Jefferson Health / Thomas Jefferson UniversitykeyStrategic or Co-development Partner · 31 March 2026Clinical trial collaboration as part of Israel-U.S. HealthTech Pilot Program to study NOL technology during spine surgery procedures at Jefferson's medical center in Philadelphia. Jefferson performs approximately 3,000 spine surgeries annually. Study aims to generate real-world clinical evidence and health economic data for U.S. market entry.
  • Blink Device CompanykeyStrategic or Co-development Partner · 28 January 2025Joint grant awarded by BIRD Foundation for development of personalized anesthesia platform incorporating NOL Nociception Monitoring. Grant accelerates development of NOL OEM module for rapid scalability and collaboration with global strategic partners.
  • Medtronic IsraelcoreChannel Partner/ Reseller/ Distributor · 12 December 2024Medtronic Israel partnership for distribution of NOL Nociception Monitoring technology. Medtronic serves as a strategic distribution partner handling sales and distribution of Medasense products in Israel market.
  • MindrayminorChannel Partner/ Reseller/ DistributorCommercial partner displaying Medasense logo on website partner section, indicating distribution or integration relationship.
  • Nihon KohdenminorChannel Partner/ Reseller/ DistributorCommercial partner displaying Medasense logo on website partner section, indicating distribution or integration relationship.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Medasense competitors and assessment

Company assessment

Direct peers

  • MDoloris Medical Systems: French medical device company that markets the ANI (Analgesia Nociception Index) monitor — the most direct competitor to Medasense's NOL technology for objective intra-operative nociception monitoring. Both target anesthesiologists with AI-derived indices for personalizing analgesic dosing.
  • Quantium Medical: Spanish developer of the qCON and qNOX nociception/antinociception monitoring indices. Competes head-to-head with Medasense's NOL in the same anesthesiology use case of guiding opioid and analgesic titration during surgery.

Broad incumbents

  • Masimo: Global patient monitoring leader whose SedLine EEG-based anesthesia monitoring and Surgical Pleth Index (SPI) overlap with Medasense's OR pain-monitoring niche. Masimo's installed base at U.S. hospitals and broad multiparameter platform make it the most likely large incumbent to compete for the same anesthesia-workflow slot.
  • Dräger: Leading anesthesia and patient monitoring vendor whose Perseus and Zeus anesthesia workstations include analgesia-monitoring adjuncts. PMD-200 attaches to Dräger-equipped ORs, positioning Dräger as both an integration partner and a potential competitor if it bundles its own nociception feature.
  • GE Healthcare: Major patient monitoring and anesthesia (Carestation) platform provider. Its installed base in U.S. ORs is the same point of attachment for Medasense, and its hemodynamic monitoring roadmap is the most likely incumbent vector for in-platform nociception features.
  • Philips: Both an integration partner (via Capsule MDIP streaming NOL data to hospital EHRs) and a broad patient-monitoring incumbent. Philips's IntelliVue and Capsule footprint make it a powerful distribution ally and a natural competitive threat if it integrates its own analgesia index.
  • Mindray: Global patient monitoring and anesthesia vendor listed as a Medasense distribution partner. Mindray's broad OR monitor portfolio and competitive pricing in emerging markets make it both a channel ally and a future bundling competitor.
  • Nihon Kohden: Japanese patient monitoring leader with significant U.S. hospital presence and listed as a Medasense distribution partner. Its anesthesia and vital signs monitors are direct attachment points for PMD-200.
  • Medtronic: Largest medical device franchise globally, currently distributing NOL in Israel through its local affiliate. Medtronic's portfolio breadth, hospital relationships, and investor arm (Baxter Ventures participated in Medasense's Series C) position it as the most strategic large incumbent — both as a near-term partner and a long-term acquirer/competitor.
  • Edwards Lifesciences: Hemodynamic monitoring leader (HemoSphere, FloTrac) competing for the same anesthesia/OR monitoring budget. While Edwards focuses on hemodynamic rather than nociception indices, its premium pricing model and KOL relationships make it a comparable high-value, evidence-driven OR monitoring franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Medasense social profiles

Digital presence

Medasense compliance and trust

Trust signal

Compliance1 record

Medasense financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medasense leadership team

Management profile

Number of profiles

Profiles2 records

Medasense funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medasense M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medasense

What does Medasense do?

Medasense develops and sells the PMD-200 patient monitor for continuous, real-time measurement of nociception during surgery and critical care. The system uses a finger-probe sensor and proprietary machine-learning algorithms to translate multiple physiological signals into an NOL Index that clinicians use to personalize analgesic dosing.

Is Medasense a public or private company?

Medasense is a private company. It is classified as venture growth investor backed and is currently operating.

When was Medasense founded?

Medasense was founded in 2008. It employs 11 to 50 people.

Where is Medasense based?

Medasense is headquartered in Ramat Gan, Israel, in the Middle East region.

How does Medasense make money?

Two revenue lines are on record. PMD-200 Hardware Sales are the primary driver. The others are distribution Partnerships.

Who are Medasense's main competitors?

Direct peers on record are MDoloris Medical Systems and Quantium Medical. Broad incumbents are Masimo, Dräger, GE Healthcare, Philips, Mindray, Nihon Kohden, Medtronic and Edwards Lifesciences.

Does Medasense have an API?

No public API is recorded for Medasense.

What industry is Medasense in?

Medasense's product category is Nociception Monitoring Systems. Its primary akta.pro industry code is HLAHACAA, Vital Signs Monitoring (Multi-parameter, Spot-Check & Continuous). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireMedasense Biometrics Receives Innovative Technology Contract from Vizient® for PMD-200™ with NOL TechnologyMedasense Biometrics received an Innovative Technology contract from Vizient for its PMD-200 pain monitoring system with NOL technology. The system objectively measures nociception to personalize analgesic dosing, and the contract was awarded after review by Vizient's client-led council. Medasense aims to bring NOL monitoring to more hospitals across the U.S.EIN PresswirePain Monitoring Data to be Available in Hospital EHRs through Philips CapsuleMedasense Biometrics announced that its PMD-200 patient monitor's NOL Index pain data will be streamed to hospital EHRs via Philips Capsule MDIP. The integration automates EMR documentation and supports vendor-neutral interoperability with major EHR systems. The device driver is now available for deployment at customer sites.EIN PresswireMedasense and Jefferson Health to Collaborate on Study of Pain Monitoring Technology in Spine SurgeryMedasense announced a collaboration with Jefferson Health's Department of Anesthesiology and Perioperative Medicine at Thomas Jefferson University to conduct a clinical trial examining the company's Nociception Level Index (NOL) pain monitoring technology during spine surgery procedures at Jefferson's medical center in Philadelphia. The study, conducted as part of the Israel-U.S. HealthTech Pilot Program, will investigate whether NOL-guided anesthesia leads to improved recovery metrics and assess associated health economics, with Jefferson performing approximately 3,000 spine surgeries annually. The collaboration is designed to generate real-world clinical evidence to support Medasense's market entry and adoption of the technology in U.S. healthcare settings.EIN PresswireMedasense Appoints MedTech Leader Peter Wehrly as Executive Chairman of the BoardMedasense announced the appointment of Peter Wehrly as Executive Chairman of the Board, effective February 25, 2026. Wehrly brings extensive MedTech experience from senior leadership roles at Medtronic and Covidien, as well as most recently serving as Board Member and U.S. President at Premia Spine. The company stated that his experience in bringing breakthrough medical technologies from early commercialization to scalable growth will support its global expansion of NOL monitoring technology.MedasenseConfident Pain ManagementMedasense is utilizing its NOL AI technology and sensor platform to transform global pain assessment and treatment by quantifying pain responses to optimize care. The company's flagship product, PMD-200™, is deployed in critical care settings to visualize pain and personalize treatment strategies.MIT Technology ReviewAI is changing how we quantify painAI-based pain assessment tools like PainChek and Medasense's PMD-200 are being adopted in healthcare settings to provide objective pain measurement for patients who cannot self-report, including those with dementia, in ICUs, and neonatal units. PainChek, which uses facial recognition AI to detect microscopic muscle movements linked to pain, has received regulatory clearance in Australia, the UK, Canada, New Zealand, and recently obtained FDA De Novo clearance in the US, logging over 10 million assessments to date. Clinical data from adopters report significant outcomes including approximately 25% reduction in antipsychotic use, 42% reduction in falls in Scotland, and improved detection of previously unrecognized pain in nonverbal patients.MedasenseMedasense and Blink Device Company awarded grant to develop an advanced anesthesia monitoring systemMedasense and Blink Device Company have been awarded a grant by the BIRD Foundation to develop a personalized anesthesia platform incorporating NOL Nociception Monitoring. This funding accelerates the development of the NOL OEM module, enabling rapid scalability for future collaborations with global strategic partners.EIN PresswireMedtronic Israel Partners with Medasense to Distribute the NOL Nociception Monitoring TechnologyMedasense and Medtronic Israel announced a strategic agreement to distribute Medasense's PMD-200 patient monitoring device with NOL technology in Israel. The device uses AI to measure pain response and is FDA-cleared for anesthesiology. The partnership aims to accelerate adoption across Israeli hospitals and clinics.Business & FinancialMedtronic Israel Partners With Medasense To Distribute The NOL Nociception Monitoring TechnologyMedasense and Medtronic Israel announced a strategic agreement to distribute Medasense's PMD-200 patient monitoring device with NOL nociception monitoring in Israel. The FDA-approved device uses AI to measure pain response, aiming to accelerate adoption across Israeli hospitals and clinics.GoogleDevice and method for determining spinal cord stimulation efficacyA patent discloses a device and method for objectively assessing spinal cord stimulation efficacy in chronic pain patients. The method uses physiological parameters like PPG and GSR to compare pre- and post-treatment measurements, enabling periodical assessment and parameter adjustment. It also predicts long-term treatment efficacy based on trial results.